Clinical Trials Browser

Phase 1 × Antineoplastic Agents × 90 days × Clear all

NCT06625593 2026-02-20

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor